Skip to main content

Advertisement

Log in

The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Al-Swiahb JN, Chen CH, Chuang HC, Fang FM, Tasi HT, Chien CY (2000) Clinical, pathological and molecular determinants in squamous cell carcinoma of the oral cavity. Future Oncol 6:837–850

    Article  Google Scholar 

  2. Morris LG, Patel SG, Shah JP, Ganly I (2010) Squamous cell carcinoma of the oral tongue in the pediatric age group: a matched-pair analysis of survival. Arch Otolaryngol Head Neck Surg 136:697–701

    Article  PubMed  Google Scholar 

  3. Olzowy B, Tsalemchuk Y, Schotten KJ, Reichel O, Harréus U (2010) Frequency of bilateral cervical metastases in oropharyngeal squamous cell carcinoma: a retrospective analysis of 352 cases after bilateral neck dissection. Head Neck May 19 (Epub ahead of print)

  4. Kuperman DI, Auethavekiat V, Adkins DR et al (2010) Squamous cell cancer of the head and neck with distant metastasis at presentation. Head Neck Sep 24 (Epub ahead of print)

  5. Zauli G, Rimondi E, Stea S et al (2008) TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 214:117–125

    Article  PubMed  CAS  Google Scholar 

  6. Di Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331–340

    Article  PubMed  Google Scholar 

  7. Soria JC, Smit E, Khayat D et al (2010) Phase 1b study of Dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28:1527–1533

    Article  PubMed  CAS  Google Scholar 

  8. Secchiero P, Zauli G (2008) TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op Hematol 15:42–48

    Article  CAS  Google Scholar 

  9. Ord RA, Blanchaert RH Jr (2001) Current management of oral cancer. A multidisciplinary approach. J Am Dent Assoc 132(Suppl):19S–23S

    PubMed  Google Scholar 

  10. Campioni D, Corallini A, Zauli G, Possati L, Altavilla G, Barbanti-Brodano G (1995) HIV type 1 extracellular tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Hu Retro 11:1039–1048

    Article  CAS  Google Scholar 

  11. Mirandola P, Ponti C, Gobbi G et al (2004) Activated human NK and CD8+ T cells express both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptors, but are resistant to TRAIL-mediated cytotoxicity. Blood 104:2418–2424

    Article  PubMed  CAS  Google Scholar 

  12. Re MC, Zauli G, Gibellini D et al (1993) Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of AIDS patients are committed to apoptotic cell death in culture. AIDS 7:1049–1055

    Article  PubMed  CAS  Google Scholar 

  13. Gibellini D, Bassini A, Pierpaoli S et al (1998) Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 160:3891–3898

    PubMed  CAS  Google Scholar 

  14. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G (2005) TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105:3413–3419

    Article  PubMed  CAS  Google Scholar 

  15. Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126–135

    Article  PubMed  CAS  Google Scholar 

  16. Kreppel M, Eich HT, Kübler A, Zöller JE, Scheer M (2010) Prognostic value of the sixth edition of the UICC’s TNM classification and stage grouping for oral cancer. J Surg Oncol 102:443–449

    Article  PubMed  Google Scholar 

  17. Macher-Goeppinger S, Aulmann S, Tagscherer KE et al (2009) Prognostic value of tumor necrosis factor-related apoptosis- inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin Cancer Res 15:650–659

    Article  PubMed  CAS  Google Scholar 

  18. van Geelen CM, Westra JL, de Vries EG et al (2006) Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 24:4998–5004

    Article  PubMed  Google Scholar 

  19. Trauzold A, Siegmund D, Schniewind B et al (2006) TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25:7434–7439

    Article  PubMed  CAS  Google Scholar 

  20. Ishimura N, Isomoto H, Bronk SF, Gores GJ (2006) TRAIL induces cell migration and invasion in apoptosis resistant cholangiocarcinoma cells. Am J Physiol 290:G129–G136

    CAS  Google Scholar 

  21. Song K, Chen Y, Goke R et al (2000) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 191:1095–1104

    Article  PubMed  CAS  Google Scholar 

  22. Giovarelli M, Musini P, Garotta G et al (1999) “Stealth Effect”: adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol 163:4886–4893

    PubMed  CAS  Google Scholar 

  23. Koyama S, Koike N, Adachi S (2002) Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol 128:73–79

    Article  PubMed  CAS  Google Scholar 

  24. Nagaraj NS, Vigneswaran N, Zacharias W (2006) Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells. J Cancer Res Clin Oncol 132:171–183

    Article  PubMed  CAS  Google Scholar 

  25. Itashiki Y, Harada K, Ferdous T, Yoshida H (2007) Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Anticancer Res 27:2365–2375

    PubMed  CAS  Google Scholar 

  26. Noutomi T, Itoh M, Toyota H, Takada E, Mizuguchi J (2009) Tumor necrosis factor-related apoptosis-inducing ligand induces apoptotic cell death through c-Jun NH2-terminal kinase activation in squamous cell carcinoma cells. Oncol Rep 22:1169–1172

    PubMed  CAS  Google Scholar 

  27. Yeh CC, Deng YT, Sha DY, Hsiao M, Kuo MY (2009) Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Mol Cancer Ther 8:2718–2725

    Article  PubMed  CAS  Google Scholar 

  28. Secchiero P, Candido R, Corallini F et al (2006) Systemic TRAIL delivery shows anti-atherosclerotic activity in apoE-null diabetic mice. Circulation 114:1522–1530

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by AIRC (to GZ) and by Carife Foundation (to PS).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paola Secchiero.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Table 1

(DOC 166 kb)

Supplementary Table 2

(DOC 168 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carinci, F., Monasta, L., Rubini, C. et al. The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. Invest New Drugs 30, 810–818 (2012). https://doi.org/10.1007/s10637-010-9586-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-010-9586-0

Keywords

Navigation